HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.

Abstract
Vulvovaginal atrophy (VVA) and dyspareunia are common problems experienced by postmenopausal women, although few seek treatment. Symptom-based therapies include nonhormonal vaginal lubricants, vaginal moisturizers, low-dose vaginal estrogen, and systemic estrogen. The 2013 United States Food and Drug Administration approval of ospemifene, an estrogen agonist/antagonist for the treatment of moderate-to-severe dyspareunia associated with VVA, increased options available to women. Several studies have evaluated the effects of ospemifene on VVA and dyspareunia and indicate an improvement in subjective findings. Objective findings such as a decrease in pH and recovery of a premenopausal vaginal maturation index have been reported. Beneficial effects have also been demonstrated in bone. Evaluations of breast health support the safety of ospemifene, although data are limited to 1 year. Short-term risks appear to be limited and include the development of hot flushes. Until additional comparative studies of ospemifene and estrogens have been performed, ospemifene should be recommended for women with symptoms of VVA and dyspareunia who are unable to tolerate or unwilling to take local or systemic estrogens. In this review, current evidence for the safety and efficacy of ospemifene in the treatment of moderate-to-severe VVA and dyspareunia are evaluated.
AuthorsAmber N McLendon, Valerie B Clinard, C Brock Woodis
JournalPharmacotherapy (Pharmacotherapy) Vol. 34 Issue 10 Pg. 1050-60 (Oct 2014) ISSN: 1875-9114 [Electronic] United States
PMID25052122 (Publication Type: Journal Article, Review)
Copyright© 2014 Pharmacotherapy Publications, Inc.
Chemical References
  • Tamoxifen
  • Ospemifene
Topics
  • Atrophy (diagnosis, drug therapy)
  • Clinical Trials as Topic (methods)
  • Dyspareunia (diagnosis, drug therapy)
  • Female
  • Humans
  • Postmenopause (drug effects)
  • Tamoxifen (analogs & derivatives, pharmacology, therapeutic use)
  • Treatment Outcome
  • Vagina (drug effects, pathology)
  • Vulva (drug effects, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: